Most of the key biotechnology and pharmaceutical companies ranging from innovative startup companies to Fortune 500 companies file patent applications with long sequence listings. This paper presents an overview of the current trends in filing long sequence listings at the USPTO. Filing long claimed sequence listings in patent applications decreases the probability of grant and has negative impact on patent term by increased number of office actions. In approximately 95% of cases, long sequence listings are reduced during prosecution and only less than 100 sequences are present in the claims of the granted patents. The paper highlights the consequences of claiming long sequence listings in the patent applications and makes recommendations to overcome them. The paper provides a platform for leading biotechnology and pharmaceutical companies to brainstorm before claiming long sequence listings in the patent applications.